| 1 |
34218294 | Epigenetic therapy in combination with a multi-epitope cancer vaccine targeting shared tumor antigens for high-risk myelodysplastic syndrome - a phase I clinical trial. | 2022 Feb |
2 |
| 2 |
31797711 | WT1 evaluation in higher-risk myelodysplastic syndrome patients treated with azacitidine. | 2020 Apr |
1 |
| 3 |
31211880 | Bone marrow WT1 levels in patients with myeloid neoplasms treated with 5-azacytidine: Identification of responding patients. | 2019 Sep |
2 |
| 4 |
28139337 | Graft-versus-leukemia effect with a WT1-specific T-cell response induced by azacitidine and donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation. | 2017 Apr |
2 |
| 5 |
28159598 | Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia. | 2017 May |
1 |
| 6 |
26284582 | Oncogene- and drug resistance-associated alternative exon usage in acute myeloid leukemia (AML). | 2016 Jan 19 |
1 |
| 7 |
24257751 | Transcriptional repression of tumor suppressor CDC73, encoding an RNA polymerase II interactor, by Wilms tumor 1 protein (WT1) promotes cell proliferation: implication for cancer therapeutics. | 2014 Jan 10 |
2 |